Claris Bio, a Jersey City, NJ-based late-clinical stage biotechnology company, raised $57M in funding.

新泽西州泽西城的晚期临床生物技术公司Claris Bio筹集了5700万美元的资金。

Backers included Novo Holdings A/S, RA Capital and Mass General Brigham Ventures and recent investor, Janus Henderson Investors.

支持者包括Novo Holdings A/S、RA Capital和Mass General Brigham Ventures以及最近的投资者Janus Henderson Investors。

The company intends to use the funds to expand operations and its development efforts.

该公司打算利用这些资金扩大业务和发展努力。

Initially funded in 2020, and led by CEO Clarke Atwell, Claris Bio is developing a recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease. Its lead program, CSB-001 Ophthalmic Solution 0.1% (oremepermin-α), brings a topical ocular biologic solution of dHGF, a molecule with the potential to restore structural and functional corneal integrity, to eyes with neurotrophic keratopathy (NK).

Claris Bio最初于2020年获得资助，由首席执行官克拉克·阿特维尔（Clarke Atwell）领导，目前正在开发一种重组人变异肝细胞生长因子dHGF，以加速和改善角膜眼病患者的角膜愈合质量。其主要项目CSB-001眼科溶液0.1%（oremepermin-α）为患有神经营养性角膜病（NK）的眼睛带来了dHGF的局部眼部生物溶液，dHGF是一种具有恢复结构和功能性角膜完整性潜力的分子。

Oremepermin-α is epitheliotropic, neurotrophic, anti-inflammatory, and anti-fibrotic, suggesting it could be an efficacious and safe option to treat many current unmet needs in diseases of the cornea. Claris expects to complete enrollment in its late-stage multi-center, randomized, double-masked, vehicle-controlled, parallel-group study, with a data readout expected in 1H2024..

Oremepermin-α具有上皮样，神经营养，抗炎和抗纤维化作用，这表明它可能是治疗角膜疾病中许多当前未满足需求的有效且安全的选择。Claris预计将完成其后期多中心，随机，双盲，车辆控制，平行组研究的注册，数据读数预计在2014年下半年完成。。

In addition to Mr. Atwell, the Claris leadership team includes CMO Susan Orr, OD, and Chief Business Officer Henry Rath. Scientific cofounders include Dr. Reza Dana, MD, MSc, MPH, and Dr. Sunil Chauhan, DVM, PhD., both from the Massachusetts Eye and Ear and the Harvard Medical School Department of Ophthalmology..

除了阿特维尔先生之外，克拉里斯的领导团队还包括首席营销官苏珊·奥尔（OD）和首席商务官亨利·拉思（HenryRath）。科学联合创始人包括医学博士、理学硕士Reza Dana博士和医学博士Sunil Chauhan博士。，来自马萨诸塞州眼耳医学院和哈佛医学院眼科。。

FinSMEs

FinSME

08/01/2024

08/01/2024